ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 48 of 121 for:    Recruiting, Not yet recruiting, Available Studies | "Tobacco Use Disorder"

Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03272685
Recruitment Status : Not yet recruiting
First Posted : September 5, 2017
Last Update Posted : March 1, 2018
Sponsor:
Collaborators:
Duke University
University of California, San Francisco
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute

Brief Summary:
This project will examine the impact of very low nicotine content (VLNC) cigarettes in a complex tobacco and nicotine product marketplace. We will compare the number of cigarettes smoked, use of alternative nicotine-containing products, biomarkers of toxicant exposure and days abstinence from cigarettes in an experimental marketplace that contains VLNC cigarettes versus normal nicotine content (NNC) cigarettes.

Condition or disease Intervention/treatment Phase
Tobacco Smoking Nicotine Dependence Drug: Very Low Nicotine Content Cigarettes Drug: Normal Nicotine Content Cigarettes Phase 3

Detailed Description:

This randomized, open label, controlled, multi-site study will simulate a "real world" tobacco environment by providing participants access to an experimental marketplace where they will be given vouchers for a specified number of points that can be exchanged for study cigarettes (varying in nicotine content described below) and non-combusted tobacco/nicotine products (smokeless tobacco, snus, electronic cigarette, medicinal nicotine replacement) or cash. More specifically, subjects (N=350 in each group) will be randomly assigned to: 1) very low nicotine content cigarettes (VLNC; 0.4 mg/g) along with non-combusted tobacco/nicotine products or 2) normal nicotine content cigarettes (NNC; 15.8 mg/g) along with non-combusted tobacco/nicotine products.

Smokers will undergo an orientation visit for screening and then enter a three phase experimental trial:

  1. Phase 1 - Baseline: Two week baseline assessment period during usual brand cigarette smoking.
  2. Phase 2 - Marketplace Adaptation: Two week period where subjects have access to the marketplace that provides their preferred usual brand cigarettes and selected non-combusted tobacco products to allow the subject to adjust to the marketplace prior to randomization;
  3. Phase 3 - Intervention: Randomization to a marketplace with access to either VLNC or NNC cigarettes plus non-combusted products for a 12 week period.

Biomarker samples are collected at baseline, end of Phase 2 and end of week 12 (Phase 3).


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 700 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase III randomized, open label, multi-center study that will examine the impact of very low nicotine content (VLNC) cigarettes using an experimental marketplace that contains and nicotine products, simulating a real world environment. There are three phases: Phase 1 is smoking usual brand cigarettes. Phase 2 is access to a marketplace with usual brand cigarettes and other non-combusted nicotine and tobacco products. Phase 3 involves access to a marketplace with study cigarettes and other non-combusted nicotine and tobacco products.
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace Part of "Evaluating New Nicotine Standards for Cigarettes"
Estimated Study Start Date : May 2018
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Very Low Nicotine Content Cigarettes
Very low nicotine content cigarettes (0.3 mg/cig nicotine yield; 9 mg of tar)
Drug: Very Low Nicotine Content Cigarettes
0.3 mg/cig nicotine yield; 9 mg tar
Other Name: Reduced Nicotine Content Cigarettes

Active Comparator: Normal Nicotine Content Cigarettes
Normal (Conventional) Nicotine Content (0.8 mg/cig nicotine yield; 9 mg of tar)
Drug: Normal Nicotine Content Cigarettes
0.8 mg/cig nicotine yield; 9 mg tar
Other Name: Conventional Nicotine Content Cigarettes




Primary Outcome Measures :
  1. Cigarettes per day (CPD) [ Time Frame: 7 days prior to end of Week 12 (12 weeks on study cigarettes) ]
    Difference in the mean cigarettes (study and non-study cigarettes) smoked per day between end of Phase 2 (experimental marketplace with usual brand cigarettes) and end of Phase 3 (experimental marketplace with study cigarettes).

  2. Cigarette avoidance [ Time Frame: 12 weeks on study cigarettes ]
    Rate of cigarette avoidance days, defined as no cigarettes smoked in the past 24 hours calculated as the proportion of cigarette avoidance days out of the total number of days in Phase 3.


Secondary Outcome Measures :
  1. Proportion of days using non-combusted tobacco/nicotine products use [ Time Frame: 12 weeks (Phase 3) on study cigarettes ]
    The proportion of days using any non-combusted tobacco/nicotine products in Phase 3 out of the total number of days in Phase 3.

  2. Percent change in Total Nicotine Equivalent (TNE) [ Time Frame: 12 weeks (Phase 3) on study cigarettes ]
    Change in Total Nicotine Equivalent (measure of nicotine and it's metabolites) from end of Phase 2 (experimental marketplace with usual brand cigarettes) to end of Phase 3 (experimental marketplace with study cigarettes).

  3. Percent change in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (total NNAL) [ Time Frame: 12 weeks (Phase 3) on study cigarettes ]
    Change in total NNAL pmol/mg creatinine, (a measure of the exposure to NNK, a tobacco specific nitrosamine) from end of Phase 2 (experimental marketplace with usual brand cigarettes) to end of Phase 3 (experimental marketplace with study cigarettes).

  4. Percent change in 8-epi-PGF [ Time Frame: 12 weeks (Phase 3) on study cigarettes ]
    Change in 8-epi-PGF (a measure of oxidative damage) from end of Phase 2 (experimental marketplace with usual brand cigarettes) to end of Phase 3 (experimental marketplace with study cigarettes).

  5. Percent change in 2-cyanoethyl-mercapturic acid (CEMA) [ Time Frame: 12 weeks (Phase 3) on study cigarettes ]
    Change in CEMA (biomarker for the mercapturic acid acrolonitrile) from end of Phase 2 (experimental marketplace with usual brand cigarettes) to end of Phase 3 (experimental marketplace with study cigarettes).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female;
  2. At least 18 years at University of MN or Duke University or 21 years of age at University of California, San Francisco;
  3. Biochemically confirmed smoker.

Exclusion Criteria:

  1. Unstable health condition;
  2. Unstable medications;
  3. Positive drug screen (except for marijuana);
  4. Pregnant or nursing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03272685


Contacts
Contact: Lori Strayer, MS 612-626-5189 strayer@umn.edu
Contact: Joni Jensen, MPH 612-624-5178 jense010@umn.edu

Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Duke University
University of California, San Francisco
Investigators
Principal Investigator: Dorothy Hatsukami, PHD University of Minnesota - Clinical and Translational Science Institute

Responsible Party: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier: NCT03272685     History of Changes
Other Study ID Numbers: 2017NTLS107
First Posted: September 5, 2017    Key Record Dates
Last Update Posted: March 1, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Intend to share findings from this research through publications and presentations. Institutions and individuals wishing to access any resources or data must contact the Principal Investigator (Hatsukami). Data will be available in two formats. One will be a summary of the data, with graphs and tables, posted as pdf files and as raw individual-level data for analysis. Data generated by this grant will be made to outside investigators, according to NIH Guidance. When data are shared, there will be no limits placed on how the data will be used. Users will agree, however, that the recipient must not transfer the data to other users and that the data are only to be used for research purposes. A record of transfer of data and a copy of the dataset that was distributed will be kept by University of Minnesota.
Time Frame: Data will not be available until primary and secondary papers are accepted for publication.
Access Criteria: Persons requesting data must do so in writing, identifying their affiliation and how the data will be used. Upon review, access will be determined.
URL: http://

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
Reduced nicotine cigarettes
Alternative nicotine products
Biomarkers of tobacco exposure

Additional relevant MeSH terms:
Tobacco Use Disorder
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Nicotine
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action